161 related articles for article (PubMed ID: 15068259)
1. Economic endpoints in clinical trials.
Cook J; Drummond M; Heyse JF
Stat Methods Med Res; 2004 Apr; 13(2):157-76. PubMed ID: 15068259
[TBL] [Abstract][Full Text] [Related]
2. The Inclusion of Economic Endpoints as Outcomes in Clinical Trials Reported to ClinicalTrials.gov.
Mitchell JM; Patterson JA
J Manag Care Spec Pharm; 2020 Apr; 26(4):386-393. PubMed ID: 32223593
[TBL] [Abstract][Full Text] [Related]
3. Power and sample size calculations for stochastic cost-effectiveness analysis.
Briggs AH; Gray AM
Med Decis Making; 1998; 18(2 Suppl):S81-92. PubMed ID: 9566469
[TBL] [Abstract][Full Text] [Related]
4. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies.
Briggs AH; O'Brien BJ; Blackhouse G
Annu Rev Public Health; 2002; 23():377-401. PubMed ID: 11910068
[TBL] [Abstract][Full Text] [Related]
5. Design issues for conducting cost-effectiveness analyses alongside clinical trials.
Ramsey SD; McIntosh M; Sullivan SD
Annu Rev Public Health; 2001; 22():129-41. PubMed ID: 11274515
[TBL] [Abstract][Full Text] [Related]
6. Analysis strategies for adaptive designs with multiple endpoints.
Chang M; Chow SC
J Biopharm Stat; 2007; 17(6):1189-200. PubMed ID: 18027225
[TBL] [Abstract][Full Text] [Related]
7. Design and analysis issues of multiregional clinical trials with different regional primary endpoints.
Tsou HH; Tsong Y; Chang WJ; Dong X; Hsiao CF
J Biopharm Stat; 2012 Sep; 22(5):1051-9. PubMed ID: 22946949
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
Bennett CL; Oddone E; Matchar D
Clin Perform Qual Health Care; 1995; 3(3):156-64. PubMed ID: 10151167
[TBL] [Abstract][Full Text] [Related]
9. Design and analysis issues for economic analysis alongside clinical trials.
Marshall DA; Hux M
Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
[TBL] [Abstract][Full Text] [Related]
10. Surrogates, meta-analysis and cost-effectiveness modelling: a combined analytic approach.
Hawkins N; Richardson G; Sutton AJ; Cooper NJ; Griffiths C; Rogers A; Bower P
Health Econ; 2012 Jun; 21(6):742-56. PubMed ID: 21796723
[TBL] [Abstract][Full Text] [Related]
11. The RTOG Outcomes Model: economic end points and measures.
Konski A; Watkins-Bruner D;
Expert Opin Pharmacother; 2004 Mar; 5(3):513-9. PubMed ID: 15013920
[TBL] [Abstract][Full Text] [Related]
12. Power and sample size determination in clinical trials with multiple primary continuous correlated endpoints.
Lafaye de Micheaux P; Liquet B; Marque S; Riou J
J Biopharm Stat; 2014; 24(2):378-97. PubMed ID: 24605975
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of genuine prior information in cost-effectiveness analysis of clinical trial data.
Stevens JW; O'Hagan A
Int J Technol Assess Health Care; 2002; 18(4):782-90. PubMed ID: 12602079
[TBL] [Abstract][Full Text] [Related]
14. Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis.
Evans WK; Coyle D; Gafni A; Walker H;
Chronic Dis Can; 2003; 24(4):102-7. PubMed ID: 14733759
[TBL] [Abstract][Full Text] [Related]
15. Efficient Research Design: Using Value-of-Information Analysis to Estimate the Optimal Mix of Top-down and Bottom-up Costing Approaches in an Economic Evaluation alongside a Clinical Trial.
Wilson EC; Mugford M; Barton G; Shepstone L
Med Decis Making; 2016 Apr; 36(3):335-48. PubMed ID: 26762649
[TBL] [Abstract][Full Text] [Related]
16. Evaluating biomarkers for prognostic enrichment of clinical trials.
Kerr KF; Roth J; Zhu K; Thiessen-Philbrook H; Meisner A; Wilson FP; Coca S; Parikh CR
Clin Trials; 2017 Dec; 14(6):629-638. PubMed ID: 28795578
[TBL] [Abstract][Full Text] [Related]
17. Statistical considerations for the next generation of clinical trials.
Wu W; Shi Q; Sargent DJ
Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519
[TBL] [Abstract][Full Text] [Related]
18. Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas.
Abel UR; Jensen K; Karapanagiotou-Schenkel I; Kieser M
J Biopharm Stat; 2015; 25(6):1285-311. PubMed ID: 25629760
[TBL] [Abstract][Full Text] [Related]
19. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
Hung HM; Wang SJ; O'Neill R
J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
[TBL] [Abstract][Full Text] [Related]
20. A combined superiority and non-inferiority approach to multiple endpoints in clinical trials.
Bloch DA; Lai TL; Su Z; Tubert-Bitter P
Stat Med; 2007 Mar; 26(6):1193-207. PubMed ID: 16791905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
